Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: Results of an open, follow-up pilot study

Acta Dermato-Venereologica

Volumn 89, Issue 2, 2009, Pages 140-144

  Gaál, János ^a   Lakos, Gabriella ^b   Szodoray, Péter ^b   Kiss, Judit ^a   Horváth, Irén ^a   Horkay, Edit ^b   Nagy, Georgina ^b   Szegedi, Andrea ^b  

^a Kenezy Korhaz Rendelointezet   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Alphacalcidol treatment; Immunomodulatory effect; Psoriatic arthropathy

Indexed keywords

ALFACALCIDOL; CD3 ANTIGEN; CD69 ANTIGEN; DICLOFENAC; GAMMA INTERFERON; METHOTREXATE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BONE DENSITY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; T LYMPHOCYTE; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ARTHRITIS, PSORIATIC; CALCIUM; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MONOCYTES;

EID: 63049126065     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0555     Document Type: Article

References (33)

1. Imazeki I, Matsuzaki J, Tsuji K, Nishimura T. Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed Res 2006; 27: 1-9.
2. Selvaraj P, Chandra G, Jawahar MS, Rani MV, Rajeshwari DN, Narayanan PR. Regulatory role of vitamin D receptor gene variants of Bsm I, Apa I, Taq I, and Fok I polymorphisms on macrophage phagocytosis and lymphoproliferative response to mycobacterium tuberculosis antigen in pulmonary tuberculosis. J Clin Immunol 2004; 24: 523-532.
3. Rigby WF, Shen L, Ball ED, Fanger MW. 1,25-Dihydroxyvitamin D3 induces a myelomonocytic phenotype with enhanced effector cell function in the HL-60 promyelocytic leukemia cell line. Mol Immunol 1985; 22: 567-572.
4. Takahashi T, Nakamura K, Iho S. Differentiation of myeloid cells and 1,25-dihydroxyvitamin D3. Leuk Lymphoma 1997; 27: 25-33.
5. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 24: 1770-1773.
6. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev 2006; 64: 226-233.
7. Mahon BD, Wittke A, Weaver V, Cantorna MT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003; 89: 922-932.
8. Cantorna MT, Mahon BD. D-hormone and the immune system. J Rheumatol Suppl 2005; 76: 11-20.
9. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-262.
10. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125: 1704S-1708S.
11. Topilski I, Flaishon L, Naveh Y, Harmelin A, Levo Y, Shachar I. The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur J Immunol 2004; 34: 1068-1076.
12. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
13. Dam TN, Moller B, Hindkjaer J, Kragballe K. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J Investig Dermatol Symp Proc 1996; 1: 72-77.
14. Jensen AM, Llado MB, Skov L, Hansen ER, Larsen JK, Baadsgaard O. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998; 139: 984-991.
15. Takahashi H, The M, Kinouchi M, Ishida-Yamamoto A, HashimotoY, Iizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31: 21-28.
16. Fairhurst DA, Ashcroft DM, Griffiths CE. Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol 2005; 6: 283-294.
17. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 1070-1078.
18. Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990; 33: 1723-1727.
19. D Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
20. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include tweniy-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
21. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005; 175: 4119-4126.
22. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25-dihydroxyvitamin D3. Diabetologia 1994; 37: 552-558.
23. Zhang AB, Zheng SS, Jia CK, Wang Y. Effect of 1,25-dihydroxyvitamin D3 on preventing allograft from acute rejection following rat orthotopic liver transplantation. World J Gastroenterol 2003; 9: 1067-1071.
24. Redaelli CA, Wagner M, Gunter-Duwe D, Tian YH, Stahel PF, Mazuchelli L, et al. 1alpha,25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int 2002; 61: 288-296.
25. Tsuji M, Fujii K, Nakamo T, Nishii Y. 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 1994; 337: 248-250.
26. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycho-lecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128: 68-72.
27. Yamauchi Y, Tsunematsu T, Konda S, Hoshito T, Itokkawa Y, Hoshizaki H. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi 1989; 29: 11-24.
28. Hein G, Oelsner P. Vitamin D metabolites in rheumatoid arthritis: findings - hypotheses - consequences. Z Rheumatol 2000; 59 Suppl 1: 28-32.
29. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64 Suppl II: ii26-ii29.
30. Szodoray P, Alex P, Chappell-Woodward CM, Madland TM, Knowlton N, Dozmorov I, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007; 46: 417-425.
31. Bito T, Roy S, Sen CK, Packer L. Pine bark extract pycnogenol downregulates IFN-gamma-induced adhesion of T cells to human keratinocytes by inhibiting inducible ICAM-1 expression. Free Radic Biol Med 2000; 28: 219-227.
32. Nishibu A, Han GW, Iwatsuki K, Matsui T, Inoue M, Akiba H, et al. Overexpression of monocyte-derived cytokines in active psoriasis: a relation to coexistent arthropathy. J Dermatol Sci 1999; 21: 63-70.
33. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hernatological patients. Acta Haematol 2002; 107: 133-144.